STOCK TITAN
  1. Home
  2. News
  3. OGN

Organon & Co. - OGN STOCK NEWS

Welcome to our dedicated news page for Organon & Co. (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organon & Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organon & Co.'s position in the market.

News
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Rhea-AI Summary
Organon (NYSE: OGN) anticipates $15 million in milestone payments in the first quarter of 2024 related to the development of a denosumab biosimilar candidate. The company will release its first quarter financial results on May 2, 2024, with milestone payments expected to impact earnings per share. Organon does not typically forecast such payments due to uncertainty. Interested parties can access the webcast for the financial results on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences earnings
-
News
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Rhea-AI Summary
Shanghai Henlius Biotech and Organon announced successful results from the phase 3 clinical trial for HLX14, a biosimilar to Prolia and Xgeva. The trial met its primary endpoints, comparing efficacy, safety, and immunogenicity in postmenopausal women with osteoporosis. Henlius and Organon have an exclusive commercialization agreement for HLX14 in various markets, excluding China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
clinical trial
-
News
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
Rhea-AI Summary
Organon (NYSE: OGN) announced that the US Department of Veterans Affairs has selected HADLIMA as a replacement for HUMIRA on the VA National Formulary. HADLIMA, a biosimilar to HUMIRA, offers a more affordable treatment option for autoimmune conditions. The CEO praised the VA's leadership in championing biosimilars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
News
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
Rhea-AI Summary
Organon (NYSE: OGN) reported a full-year 2023 revenue of $6.3 billion, up 1% as-reported and 3% at constant currency. The company's full-year 2023 diluted earnings per share were $3.99, with non-GAAP adjusted diluted earnings per share at $4.14. Adjusted EBITDA for 2023 was $1.9 billion, with a 31.0% margin. Organon provided full-year 2024 financial guidance with revenue expected in the range of $6.2 billion to $6.5 billion and an Adjusted EBITDA margin of 31.0% to 33.0%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.81%
Tags
earnings
-
News
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
Rhea-AI Summary
Organon, a global healthcare company focusing on women's health, will release its Q4 and full year 2023 financial results on February 15, 2024. The company will host a webcast and conference call at 8:30 a.m. EST. Interested parties can access the live call via webcast and a replay will be available on the company's website. Institutional investors and analysts must register in advance to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
conferences
-
News
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
Rhea-AI Summary
Organon (OGN) introduces XACIATO™ (clindamycin phosphate) vaginal gel 2% to treat bacterial vaginosis, a common condition affecting millions of women. The gel aims to address the physical and emotional impact of BV, disproportionately affecting non-Hispanic Black and Mexican American women. XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
none
News
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
Rhea-AI Summary
Organon (NYSE: OGN) affirms prior revenue and Adjusted EBITDA guidance for full year 2023, expects free cash flow to be above previous range, and provides financial objectives for 2024. The company's annual dividend of $1.12 per share remains its primary capital allocation priority.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.12%
Tags
none
-
News
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Organon (NYSE: OGN) CEO and CFO to participate in fireside chat at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
conferences
-
News
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Rhea-AI Summary
Organon (NYSE: OGN) becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe, expanding its product portfolio in the central nervous system disorders. The agreement with Eli Lilly and Company (Lilly) involves an upfront payment of $50 million and sales-based milestone payments, with the transaction expected to close in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
News
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Organon (OGN) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
Stock OGN logo
Organon & Co.

NYSE:OGN

OGN Rankings

#1243 Ranked by Market Cap
#4448 Ranked by Stock Gains
#467 Ranked by Dividends

OGN Stock Data

4.46B
254.87M
0.14%
79.96%
4.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Kenilworth

About OGN

organon is a dutch pharmaceutical company started in oss the netherlands. it is famous for "the pil" a birthcontrol pil. organon grew as a company and was taken over by schering plough and later on by merck and continues as msd in the netherlands. in the old days the compant was great, it used to be "gezellig" !